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Corticosteroids for Acute Bacterial Meningitis
Brian M. Greenwood, M.D.
Death and long-term disabilities are common 
outcomes of acute bacterial meningitis, especially 
in developing countries, even when highly effec-
tive antibiotic therapy is given. Therefore, improve-
ment in the outcomes of acute bacterial menin-
gitis is unlikely to come from developments in 
chemotherapy but rather from measures that al-
leviate the damage done before the causative bac-
teria are killed. Some of this damage is caused 
by bacterial toxins, but experiments in animals 
suggest that host inflammatory responses induced 
by bacterial products are also involved.1 Thus, 
there are strong theoretical grounds for believ-
ing that antiinflammatory drugs should improve 
the outcomes of acute bacterial meningitis. Estab-
lishing whether this is the case has taken more 
than 25 years,2 and the situation is still not entire-
ly clear.
Many of the early trials of corticosteroid 
therapy in acute bacterial meningitis were under-
powered and had flaws in their designs. How-
ever, there is now a consensus, based largely on 
the results of meta-analyses rather than on indi-
vidual, definitive trials, that in industrialized 
countries, the administration of dexamethasone 
to children with acute Haemophilus influenzae type b 
meningitis before the start of antibiotic therapy 
reduces the incidence of sequelae, especially deaf-
ness.3 The increasing use of the H. inf luenzae 
type b conjugate vaccines is reducing the burden 
of disease caused by this pathogen. The effect of 
dexamethasone on meningitis caused by other 
bacteria is less certain. Nevertheless, the admin-
istration of dexamethasone is now widely accept-
ed as standard practice in the management of 
acute bacterial meningitis in children in the in-
dustrialized world. There is evidence, based large-
ly on the results of a large multicenter trial in 
Europe, that dexamethasone also improves out-
comes in adults in industrialized countries.4,5 
Can these findings be translated to the devel-
oping world, where acute bacterial meningitis is 
many times more prevalent than it is in wealthy 
countries?
The results of some early studies of cortico-
steroid therapy for the management of acute bac-
terial meningitis in children in less developed 
countries were encouraging.6-8 However, a trial 
involving 598 Malawian children, about one third 
of whom were positive for the human immuno-
deficiency virus (HIV), provided convincing evi-
dence of a lack of any benefit.9 The negative out-
come of this large, well-conducted trial has 
persuaded most pediatricians practicing in Africa 
that the routine administration of corticosteroids 
to children with acute bacterial meningitis is not 
indicated. Results from another Malawian trial 
suggest that, in this part of Africa, the same 
may be true for adults.
In this issue of the Journal, Scarborough et al.10 
report the results of a trial of dexamethasone in 
465 Malawian patients 16 years of age or older 
with acute bacterial meningitis. Dexamethasone 
was given at a dose of 16 mg twice daily for 4 days 
in conjunction with ceftriaxone (given intravenous-
ly or intramuscularly in a nested, factorial trial). 
Overall mortality at 40 days after enrollment was 
high (54%) and did not differ significantly be-
tween patients who received dexamethasone 
(56%) and those who received placebo (53%) 
(odds ratio, 1.14; 95% confidence interval [CI], 
0.79 to 1.64). The rates of disability or death or 
clinically detectable hearing loss 1 month after 
enrollment or of death 6 months after enroll-
ment were not different between the groups. 
Multiple subanalyses, including one subanalysis 
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restricted to patients with proven bacterial men-
ingitis, showed no evidence of a protective effect 
of dexamethasone in any patient subgroup.
In contrast to these findings in Malawi, a 
study conducted in Vietnam by Mai et al.,11 also 
reported in this issue of the Journal, came to a 
different conclusion. This trial randomly assigned 
435 subjects older than 14 years of age to receive 
dexamethasone at a dose of 0.4 mg per kilogram 
of body weight every 12 hours for 4 days or pla-
cebo before the administration of ceftriaxone. 
More than half of the patients had received anti-
biotics before enrollment in the trial. Overall, 
there were no significant differences in outcomes 
between the two treatment groups, although 
there was a trend in favor of patients who had 
received dexamethasone. One month after enroll-
ment, overall mortality in the patient group was 
11%: 10% in the dexamethasone group and 12% 
in the placebo group (relative risk of death, 0.79; 
95% CI, 0.45 to 1.39). However, when the analy-
sis was restricted to patients with proven bacte-
rial infection, differences in mortality between 
the groups were seen at 1 month after enrollment 
(relative risk of death, 0.43; 95% CI, 0.20 to 0.94) 
and in the rate of disability or death at 6 months 
(odds ratio, 0.56; 95% CI, 0.32 to 0.98). Deafness 
was reduced significantly in the dexamethasone 
group. Surprisingly, the patients with probable 
meningitis who received dexamethasone had a 
higher mortality rate (although not significantly 
so) at 1 and 6 months after enrollment than the 
controls. The authors suggest that this result may 
have been due to the inclusion of patients with 
tuberculous meningitis in this group in whom 
corticosteroid therapy without concomitant anti-
tuberculosis therapy was harmful.
How can the difference in results between 
these two trials be explained? Both trials were 
well designed, included sufficient numbers of pa-
tients to show a moderately large protective ef-
fect, and were conducted by experienced investi-
gators in hospitals with reasonable resources. 
Both studies used an effective antibiotic (ceftri-
axone) and a similar dose of dexamethasone. In 
Malawi, the predominant pathogen was Strepto-
coccus pneumoniae; in Vietnam, the predominant 
pathogen was S. suis, which is similar in many 
ways to S. pneumoniae. The most striking differ-
ence between the two studies is the much higher 
overall mortality in Malawi than in Vietnam (54% 
vs. 11%). This high rate of death may have been 
due in part to the very high HIV prevalence 
among the Malawian patients (90%), although a 
rate of death of approximately 50% among Afri-
can patients with pneumococcal meningitis in 
areas where HIV is not prevalent has been de-
scribed frequently. The HIV positivity rate was 
1% in the Vietnamese study. Perhaps pathogenic 
changes were too far advanced in the African pa-
tients to be influenced by adjuvant therapy.
What are the practical messages provided by 
the results of these two important studies for cli-
nicians who care for patients with acute bacte-
rial meningitis in the developing world? In Africa, 
there seems to be little justification for giving 
dexamethasone, which may present a consider-
able drain on limited budgets, to children in any 
country or to adults in areas where the preva-
lence of HIV is high. Evidence is lacking for the 
treatment of adults in areas with a low incidence 
of HIV infection and for the treatment of pa-
tients with meningococcal meningitis, an impor-
tant cause of deafness in sub-Saharan Africa, 
in areas where this infection is epidemic.12 A 
case could be made for undertaking further trials 
in these groups. In Vietnam, there is now good 
evidence that, as in Europe, where mortality as-
sociated with acute bacterial meningitis is also 
relatively low, dexamethasone helps adults with 
proven acute bacterial meningitis, and this find-
ing may be applicable to other parts of South-
east Asia. However, the trend toward a higher 
rate of death among patients with probable bac-
terial meningitis suggests that corticosteroids 
should be given only when a diagnosis can be 
made promptly by means of Gram’s stain or a 
rapid diagnostic test before the start of treat-
ment. In other parts of the developing world, 
such as the Indian subcontinent, there is insuf-
ficient evidence on which to base a decision. In 
South America, results of a recent multicenter 
study suggest that dexamethasone is ineffective 
in children with acute bacterial meningitis but 
that glycerol, given alone or with dexamethasone, 
protects against severe neurologic sequelae.13
The debate about the value of corticosteroids 
in acute bacterial meningitis will continue. How-
ever, it seems likely that in the developing world, 
the use of corticosteroids or other adjunctive ther-
apies will have only a marginal effect on survival. 
The goal should be to prevent most forms of 
these devastating infections, which are associated 
with a high morbidity, through the widespread 
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use of the conjugate vaccines that are becoming 
increasingly available.
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